Trial Profile
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Crizotinib; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CheckMate 370
- Sponsors Bristol-Myers Squibb
- 12 Mar 2021 Status changed from active, no longer recruiting to completed.
- 01 Jul 2019 Planned End Date changed from 15 Apr 2019 to 15 Mar 2020.
- 01 Jul 2019 Planned primary completion date changed from 15 Apr 2019 to 15 Mar 2020.